Clinical Trial Update: Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS [Phase 2]

View source ↗

Summary

Open-label extension of efgartigimod in adults with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome; the Phase 2 study was terminated, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-covid-19 Postural Orthostatic Tachycardia Syndrome
• Postural Orthostatic Tachycardia Syndrome

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2025-10-23